A Pilot Study to Develop Predictive Biomarkers for the Response to Immunotherapy in Lung Cancer

Completed

Conditions studied: Lung Cancer

In brief

Several immune checkpoint inhibitors targeting the PD-1 pathway have been developed with clinical trials showing an approximately 20% durable response in unselected patients with advanced non-small cell lung cancer (NSCLC). At the moment, no clear biomarker exists to accurately predict anti-PD1/PDL1 tumor responsiveness. The goal of this study is to broadly discover and evaluate the utility of blood based biomarkers for use in measuring and predicting response to immunotherapy in patients with lung cancer.

Key facts

Study ID

NCT03047616

Run by

Abramson Cancer Center at Penn Medicine

People needed

88

Starts

2016-11-22

Expected to finish

2019-05-31

Last updated by the study team

2021-04-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced Metastatic NSCLC
• Scheduled to initiate an immune checkpoint inhibitor
• Age >= 18 years
• Able to provide informed consent

You may not qualify if…

• Other, unrelated, concomitant active, invasive malignancy

Where it is running

• Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.